Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease

Mise à jour : Il y a 5 ans
Référence : NCT02224820

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

IdeS is an immunoglobulin g (IgG) cleaving enzyme. It will given to patients with donor specific antibodies to reduce the antibody load and thus enable kidney transplantation. IdeS antibody reducing efficacy and its safety will be studied.


Critère d'inclusion

  • chronic kidney disease

Liens